









All the values are expressed as mean±SEM, n=6, One way analysis of variance (ANOVA) followed by multiple comparison Dunnett's test, \*\*\*p<0.001 as compared to control group.


**3.4.3 Effect of ethanolic extract of *Momordica dioica* on pentobarbitone induced sleeping time in mice.**

The Time between injection of pentobarbitone and onset of sleep in all treated groups (onset of latency time) presented in (table 4). Ethanolic extract of *Momordica dioica* in the doses of 200 and 400mg/kg shortened the onset of latency time of sleep to 200 (6.34±0.41) and 400mg/kg (5.40±0.35) respectively which lower than that of control group (9.50±0.56) and is significant comparable to diazepam also (5.57±0.56). Duration of sleeping time in animals receiving 200 and 400mg/kg of ethanolic extract doses increased to 56.73±1.33 and 52.91±0.87 that was highly significant (p<0.001) compared with control group (26.95±1.18). There was a significant (p<0.001) increased in duration of sleep in diazepam group (43.96±1.04) when compared to control group.

**Table 4:** Effect of ethanolic extract of *Momordica dioica* on pentobarbitone induced sleeping time in mice

Treatment Groups	Onset of Sleep	Duration of sleep
Control	9.50±0.56	26.95±1.18
Standard (Diazepam 5mg/kg)	5.57±0.25***	43.96±1.04***
EMD 200mg/kg	6.34±0.41***	56.73±1.33***
EMD 400mg/kg	5.40±0.35***	52.91±0.87***

All the values are expressed as mean±SEM, n=6, One way analysis of variance (ANOVA) followed by multiple comparison Dunnett's test, \*\*\*p<0.001 as compared to control group.



**Figure 4:** Effect of ethanolic extract of *Momordica dioica* on duration of sleep in pentobarbitone induced sleeping time in mice.

All the values are expressed as mean±SEM, n=6, One way analysis of variance (ANOVA) followed by multiple comparison Dunnett's test, \*\*\*p<0.001 as compared to control group.

**3.4.4 Effect of ethanolic extract of *Momordica dioica* on Hole board (No. of head poking and duration of head dips).**

Administration of different doses of EMD 200 (38.00±0.35) and 400mg/kg (37.64±0.94) had significantly increased no. of hole poking in mice as compared to control group (33.23±0.95). The mice treated with standard drug


diazepam produced s significant increase in no. of hole pokings by 46.21±1.11. (Table no 5)

Administration of different doses of EMD 200 (13.50±1.17) and 400mg/kg (14.67±1.14) had significantly increased duration of head dips in mice as compared to control group (8.33±0.88). The mice treated with standard drug diazepam produced s significant increase in duration of head dips by 22.50±1.25 (Figure no 5, 6).

**Table 5:** Effect of ethanolic extract of *Momordica dioica* on Hole board (No. of head poking and duration of head dips).


Treatment Groups	No. of Head Poking	Duration of head Dips
Control	33.23±0.95	8.33±0.88
Standard (Diazepam 5mg/kg)	46.21±1.11***	22.50±1.25***
EMD 200mg/kg	38.00±0.35**	13.50±1.17*
EMD 400mg/kg	37.64±0.94***	14.67±1.14**

All the values are expressed as mean±SEM, n=6, One way analysis of variance (ANOVA) followed by multiple comparison Dunnett's test, \*p<0.05, \*\*p<0.01, \*\*\*p<0.001 as compared to control group.



**Figure 5:** Effect of ethanolic extract of *Momordica dioica* on Hole board (No. of head poking).

All the values are expressed as mean±SEM, n=6, One way analysis of variance (ANOVA) followed by multiple comparison Dunnett's test, \*\*p<0.01, \*\*\*p<0.001 as compared to control group.



**Figure 6:** Effect of ethanolic extract of *Momordica dioica* on Hole board (duration of head dips)

All the values are expressed as mean±SEM, n=6, One way analysis of variance (ANOVA) followed by multiple comparison Dunnett's test, \*p<0.05, \*\*p<0.01, \*\*\*p<0.001 as compared to control group.

#### 4. Conclusion and Discussion

It can be concluded from the study that the anticonvulsant and antidepressant effects of the ethanolic *Momordica dioica* may be via non-specific mechanisms. However, extensive studies are needed to evaluate the precise mechanism(s), active principles, and the safety profile of the plant as a medicinal remedy for convulsive and depression disorders. The results of the present study indicate that ethanol extract of *Momordica dioica* (EMD) possesses anticonvulsant activity in mice. GABA is the major inhibitory neurotransmitter in the brain while glutamic acid is an excitatory neurotransmitter in the brain. The inhibition of GABA neurotransmitter and the enhancement of the action of glutamic acid have been shown to be the underlying factors in epilepsy<sup>41,42</sup>. Our study shows that the ethanol extract of *Momordica dioica* protected some of the animals against seizures induced by maximal electroshock, PTZ and INH also delayed the latency of the seizures.

In the present study maximal electroshock produced seizures in all the animals used. Antiepileptic drugs that block MES-induced tonic extension are known to act by blocking seizure spread. Moreover, drugs that inhibit voltage-dependent Na<sup>+</sup> channels, such as phenytoin can prevent MES-induced tonic extension<sup>43,44</sup>.

PTZ induced seizure is commonly used model for screening of drugs effective in absence seizures. In present study EMD in the dose of 200 and 400mg/kg increased latency of onset of first myoclonic jerk, onset of clonus and decreased total mortality though it was statistically significant in the dose of 400 mg/kg it produced statistically significant ( $P < 0.001$ ) protective effect. Combination of therapeutic dose of diazepam 5mg/kg with EMD showed significant ( $P < 0.05$ ) antiepileptic activity as compared to vehicle control group. PTZ is a CNS stimulant which acts by inhibiting chloride channels of  $\gamma$ -amino butyric acid receptor (GABA) complex<sup>115</sup>. Inhibition of stimulant activity of PTZ might be responsible for antiepileptic activity of *Momordica dioica*. PTZ produces oxidative stress to neuronal cell.<sup>48</sup>

Isoniazid is used widely for the treatment and chemoprophylaxis of Tuberculosis, but can have serious effects on the central nervous system causing seizures and comas<sup>49</sup>. The factor responsible for INH-induced epileptic seizure is the decrease of GABA below a critical level in some neurons. Perhaps the decrease in the amount of GABA stored presynaptically causes a reduction in the amount of GABA released by nerve impulses. Hence, the GABA receptors are regulated at the level of maximal sensitivity in order to maximize the action of GABA. Diazepam treated group showed 100% protection of the animals. INH-induced epileptic seizure in mice significantly delayed the onset of seizures. The test drug treated groups showed protection of the animals suggesting that ethanolic extract of *Momordica dioica* leaves has antiepileptic activity.

In the present study, we studied antidepressant activity of the ethanolic extract of *Momordica dioica*, in mice. We used two animal models, pentobarbitone induced sleeping and exploratory activity for antidepressant study. Diazepam which belongs to the benzodiazepine group is a central nervous system depressant used in the management of sleep disorders such as insomnia. Benzodiazepines have a binding site on GABA receptor type-ionophore complex (GABAA)<sup>52,53</sup>. They decrease activity, moderate excitement and calm the recipient. Substances like diazepam (the reference drug used in this study) reduce onset of and increase duration of barbiturate-induced sleep and reduce exploratory activity possessing potentials as sedative<sup>53</sup> EMD after oral administration of 200 and 400 mg/kg doses produced sedative effect similar to that observed with 5 mg/kg diazepam. Diazepam is a very well-known anxiolytic benzodiazepine which produces not only anxiolytic-like effect, but also important sedative action. It is possible that the tranquillizing activity of EMD is mediated by GABAergic system, since it can produce profound sedation in mice<sup>54</sup>.

The inhibitory action of GABA consists in the opening of chloride channels to allow hyper polarization of the membrane, leading to CNS depression and resulting in sedative and hypnotic activity. Glutamate and GABA are quantitatively the most important excitatory and inhibitory neurotransmitters, respectively, in the mammalian brain. Thus, receptors for these two neurotransmitters are regarded as the important targets for psychotropic drugs. In the test of pentobarbital-induced sleeping in mice, the potentiated effect of EMD in mice was represented. It not only prolonged the sleeping time, but also decreased the latency of falling asleep and increased the sleep onset. Since the effect of barbiturates on the CNS involves activating of the inhibitory GABAergic system, the result of the present study suggests that some ingredients in EMD produce facilitation of this inhibitory system.

Depressive disorders accompany most of the clinical condition including cardiovascular disorders, thyroid disorders and post partum condition. In view of this there is an urgent need of a drug that can overcome both these symptoms. Various plant based products identified to possess neuropharmacological properties. Which might prove useful as a therapeutic agent in these disorders. The hole board test provides a simple method for measuring the response of animal to an unfamiliar environment and is widely used to assess the emotionality, anxiety and/or responses to stress in animals. The extract of EMD was observed to have a significant effect on a hole poking and duration of time, which further justifies its depressive effect.

#### References

- [1] Gardiner RM, Lehesjoki AE. Genetics of the epilepsies. *Curr Opin neurol* 2000;13:157-164.
- [2] Bhattacharya Salil K, Sen Parantapa, Ray Arunabha. Motor disorders, In: Das Prasun K.(ed.) *Pharmacology*. 2nd Ed. New Delhi: Elsevier, 2004:247-252.
- [3] Gardiner RM. Genetics of epilepsies. In: Sinha KK, Chandra P. eds. *Advances in Neurosciences*. Vol – 2,

- Kolkata: Association of Neuroscientists of Eastern India, 2001:155-176.
- [4] Gangopadhyay PK, Biswas Atanu, Senapati AK and Gangopadhyay Gautam. Genetics of Epilepsies. Jour Ind Med Assoc. (JIMA) 2004,102 (02):71-72. K. Deb, S. Agrawal, A. Pratab, T. Meyarivan, "A Fast Elitist Non-dominated Sorting Genetic Algorithms for Multiobjective Optimization: NSGA II," KanGAL report 200001, Indian Institute of Technology, Kanpur, India, 2000. (technical report style)
- [5] Bennett PN, Brown MJ. Epilepsy, Parkinsonism and allied conditions. In Clinical Pharmacology. Churchill Living Stone, 9th ed. chapter 20, 2003:413-422
- [6] [McNamara JO. Drugs effective in therapy of epilepsies. In: Goodman and Gilmans, The Pharmacological basis of therapeutics, McGrawHill, 10th ed; chapter 21, 2001; 521- 547.
- [7] Katzung BG. Antiseizure drugs. In Basic Clinical Pharmacology, McGraws Hill, 9th ed. Chapter 24, 2004:379-400.
- [8] Gardiner RM, Lehesjoki AE. Genetics of the epilepsies. Curr Opin neurol 2000;13:157-164.
- [9] Bhattacharya Salil K, Sen Parantapa, Ray Arunabha. Motor disorders, In: Das Prasun K. (ed.) Pharmacology. 2nd Ed. New Delhi: Elsevier, 2004:247-252.
- [10] Gardiner RM. Genetics of epilepsies. In: Sinha KK, Chandra P. eds. Advances in Neurosciences. Vol – 2, Kolkata: Association of Neuroscientists of Eastern India, 2001:155- 176.
- [11] Gangopadhyay PK, Biswas Atanu, Senapati AK and Gangopadhyay Gautam. Genetics of Epilepsies. Jour Ind Med Assoc. (JIMA) 2004,102 (02):71-72.
- [12] Bennett PN, Brown MJ. Epilepsy ,Parkinsonism and allied conditions. In Clinical Pharmacology. Churchill Living Stone, 9th ed. chapter 20, 2003:413-422.
- [13] McNamara JO. Drugs effective in therapy of epilepsies. In: Goodman and Gilmans, The Pharmacological basis of therapeutics, McGrawHill, 10th ed; chapter 21, 2001; 521- 547.
- [14] Katzung BG. Antiseizure drugs. In Basic & Clinical Pharmacology, McGraws Hill, 9th ed. Chapter 24, 2004:379-400.
- [15] Dulac O, Leppik I. Initiating and discontinuing treatment. In: Engel J Jr, Pedley TA, eds. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven, 1997:1237-46.
- [16] Leestma JE, Annegers JF, Brodie MA, et al. Sudden unexplained death in epilepsy: observations from a large clinical development programme. Epilepsia 1997;38:47-55.
- [17] Reviews the subject and identifies overall risk and factors associated with greater risk of SUDEP. Schierhout G, Roberts I. Prophylactic antiepileptic agents after head injury: a systematic review. J Neurol Neurosurg Psychiatry 1998;64:108-12.
- [18] Clearly demonstrates that long term prophylactic antiepileptic drug treatment after head injury is not indicated.
- [19] Berg AT, Shinnar S. The risk of recurrence following a first unprovoked seizure. Neurology 1991;41:965-72.
- [20] Stahl, S. (2000) Psychopharmacology 2nd edition, New York, Cambridge University Press.
- [21] Mulrow, C.D., Williams, J.W. jr., Trivedi, M., Chiquette, E., Aguilar, C., Cornell, J.E., Badgett, R., Noel, P.H., Lawrence, V., Lee, S., Luther, M., Ramirez, G., Richardson, W.S., Stamm, K (1998) Treatment of depression newer pharmacotherapies *Psychopharmacol bull.* 34(4):409-795.
- [22] Stahl, S. (2000) Psychopharmacology 2nd edition, New York, Cambridge University Press.
- [23] Van Oekelen, D., Luyten, W.H.M.L., Leysen, J.E. (2003) 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors and their atypical regulation properties. *Life Sciences* 72:2429-2449.
- [24] Stahl, S. (2000) Psychopharmacology 2nd edition, New York, Cambridge University Press.
- [25] Van Praag, H.M. (1982) Neurotransmitters and CNS disease. *The Lancet* 2:1259-63
- [26] Bowden, C., Cheetham, S.C., Lowther, S., Katona, C.L.E., Crompton, M.R., Horton, R.W. (1997)
- [27] Dopamine uptake sites, labeled with [3H] GBR12935, in brain samples from depressed suicides and controls. *European Neuropsychopharmacology* 7(4) 247-252.
- [28] Harvey, B.H., Jonker, L.P., Brand, L., Heenop, M., Stein D. (2002) NMDA receptor involvement in imipramine withdrawal-associated effects on swim stress, GABA levels and NMDA receptor binding in rat hippocampus. *Life Sciences* 71:43-54.
- [29] Heresco-Levy, U., Javitt, D.C. (1998) The role of N-methyl-D-aspartate (NMDA) receptor mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes. *European Neuropsychopharmacology* 8:141-152.
- [30] Green, A.R., Aronson, J.K., Curson, G., Woods, H.F. (1980) Metabolism of an oral tryptophan load. In: Effects of dose and pretreatment with tryptophan. *Br. J. Clin. Pharmacol.* 10:603-610.
- [31] Gal, E.M., Sherman, A.D. (1980) L-Kynurenine: its synthesis and possible regulatory function in the brain. *Neurochemistry Research* 5:223-239.
- [32] Badawy, A.A.-B., Punjani, N.F., Evans, M. (1981) The role of liver tryptophan pyrrolase in the opposite dependence on brain tryptophan metabolism. *Journal of Biochemistry* 196:161.
- [33] Müller, W.E., Kasper, S. (1997a) Clinically used antidepressant drugs. *Pharmacopsychiatry* 30(2):S102-7.
- [34] Potter, W.Z., Hollister, L.E. (1998) Antidepressant agents. *Basic and Clinical Pharmacology* (7th edition) Edited by Bertram G Katzung, Appleton & Lange, Stamford, Connecticut: 483-495.
- [35] Waller, D.G., Renwick, A.G., Hillier, K. (2001) Depression in Medical Pharmacology and Therapeutics. Edited by Saunders, W.B., Harcourt Publishers Limited, London: 251-262.
- [36] Besson, A., Privat, A.M., Eschalièr, A., Fialip, J. (1999) Dopaminergic and opiodergic mediations of tricyclic antidepressants in the learned helplessness paradigm. *Pharmacol Biochem Behav.* 64(3):541-548.
- [37] Musicco M, Beghi E, Solari A, et al. Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. First seizure trial group (FIRST group). *Neurology* 1997;49:991-8.
- [38] The wealth of India. Vol. 6. Publication and Information Directorate. CSIR, New Delhi. 1962; 411.

- [39] Raj NM, Prasanna KP, Peter KV. *Momordica* spp. In: Kallo G, Bergh BO (Eds.). *Genetic Improvement of Vegetables Crops*. Pergamon Press: Oxford. 1993; 239–243.
- [40] Musicco M, Beghi E, Solari A, et al. Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. First seizure trial group (FIRST group). *Neurology* 1997;49:991–8.
- [41] M. Parvathi and K. Ravishankar. Evaluation of Antidepressant, Motor Coordination and Locomotor Activities of Ethanolic Root Extract of *Clitoria Ternatea*. *Journal of Natural Remedies* January 2013. Vol 13 (1).
- [42] Westmoreland BF, Benarroch EE, Dube JR, Regan TJ, Sandok BA. *Medicinal neurosciences*, Rochester: Margo Foundation, 1994, pp 307-312.
- [43] Rang HP, Dale MM, Ritter JM, Moore PK. *Pharmacology* 5th ed. India: Churchill Livingstone, 2005 pp 456-473.
- [44] Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising development stage compounds, *Pharmacol Rev* 1990; 42: 223-286.
- [45] MacDonald RL, Kelly KM. Antiepileptic drug mechanisms of action. *Epilepsia* 1995; 36: S2-S12.
- [46] Mukherjee PK. *Quality control of Herbal Drugs*. 1st ed. New Delhi: Business Horizons Pharmaceutical publishers, 2001.
- [47] Gerhard Vogel H and Wolf gang H: *Drug discovery and evaluation pharmacological assays*. Springer-Verlag Berlin Heidelberg, New York. Fourth Edition 2002.
- [48] Curtis DR, Game CJA and Lodge D: Benzodiazepines and central glycine receptors. *Br.J. Pharmacol* 1976; 56: 307-311.
- [49] Sembulingam K, Sembulingam P, Namasiyam A. *Indian J. Physiol Pharmacol*. 41: 139-143.
- [50] Pemminati S, Gopalakrishna HN, Ashok K Shenoy, Sahu SS, Mishra S, Meti V, Vinod N. Antidepressant activity of aqueous extract of fruits *Embllica off cinalis* in mice. *Int J. Applied Biology and Pharmaceutical Technology*. 2012 Oct; 1(2):449-454.
- [51] Leewanich P, Tohda M, Matsumoto K, Subhadhirsakul S, Takayama H, Watanabe H. Behavioral studies on alkaloids extracted from the leaves of *Hunteria zeylanica*. *Biological and Pharmaceutical Bulletin*. 1996;19(3):394-399.
- [52] Adeyemi OO, Yetmitan OK, Taiwo AE. Neurosedative and muscle-relaxant activities of ethyl acetate extract of *Baphia nitida* AFZEL. *J. Ethnopharmacol*. 2006 May;106(3):316-323.
- [53] Hemby SE, Lucki I, Gatto G, Singh A, Thornley C, Matasi J, et al. Potential antidepressant effects of novel tropane compounds, selective for serotonin and dopamine transporters. *J. Pharmacol Exp Ther*. 1997 Aug; 282: 727-733.
- [54] Gottesmann C. GABA mechanisms and sleep, *Neuroscience* (2002) 111: 231-239.

## Author Profile

**Silpa Sundur** received M Pharmacy from Manipal College of Pharmaceutical Sciences and now Research Scholar at Jawaharlal Nehru Technological University in the Department of Pharmacology and Asst. Professor in Anwarul Uloom College of Pharmacy, JNTUH, Telangana, India.

**Md. Abdul Moiz** received B. Pharmacy from JNTU and now pursuing M Pharmacy from Jawaharlal Nehru Technological University, Anwarul Uloom College of Pharmacy, Telangana, India.

**V. L. Jaya Sekhar** received B Pharmacy from The TamilNadu Dr. M. G. R Medical University and M. Pharmacy from Kakatiya University, Telangana, India.